Jake King | TalkMarkets | Page 1

Jake King

A leading online destination for actionable equity research in healthcare.
Contributor's Links: PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer regular market ...more
Following: 5 Followers: 2985

All Contributions

Latest Posts
1 to 11 of 11 Posts
Your 30-Second Primer On This Week's Hottest IPO, Spark Therapeutics
Friday, January 30, 2015 11:54 AM EDT
Spark Therapeutics (ONCE) lists publicly today, joining companies like bluebird bio (BLUE) and Avalanche (AAVL) as yet another emerging gene therapy player.
In this article: BLUE, PFE, AAVL, QURE, ONCE
Read
On Bluebird Bio After A Glimpse Of Preliminary Lentiglobin Data
Wednesday, November 12, 2014 3:26 PM EDT
Last week, preliminary data for Bluebird Bio's Lentiglobin were released as part of the abstract dump for ASH in December. Here's what you need to know.
In this article: BLUE
Read
ASH 2014 Abstracts Are About To Hit: Here Are Some Of The Names To Follow
Thursday, November 6, 2014 8:30 AM EDT
One of the biggest events in healthcare annually, the American Society of Hematology’s annual meeting (56th!) begins on December 6, but abstracts from the conference will be released this morning. Here's a primer on the stocks to watch.
In this article: BMY, MRK, GERN, TGTX, EPZM, AGIO, KPTI, KITE, BLUE
Read
Consider The 2-3x Upside In This Most Overlooked Hepatitis B Stock
Tuesday, November 4, 2014 1:32 PM EDT
GlobeImmune IPO’d in June to little fanfare and has underperformed the biotech sector considerably since then. A key driving event in the next six months should put it back on the radar.
In this article: ALNY, CELG, GILD, ARWR, GBIM
Read
Being Early On An Early Asset: Trillium May Be A Diamond In The Rough Immunotherapy Stock
Wednesday, October 29, 2014 9:59 AM EDT
Trillium Therapeutics is an immuno-oncology company developing novel cancer therapeutics. Their primary target, the CD47 antigen, is generating significant attention from industry and academia alike.
In this article: TRIL, CELG
Read
Sarepta Hits Another Roadblock Prior To Eteplirsen New Drug Application
Monday, October 27, 2014 5:32 PM EDT
On Monday morning, Sarepta Therapeutics (SRPT) held a teleconference concerning regulatory updates for Eteplirsen, the company's lead drug candidate for Duchenne Muscular Dystrophy.
In this article: RNA, SRPT
Read
Pfizer Drops Remoxy: Durect And Pain Therapeutics Suffer
Monday, October 27, 2014 1:39 PM EDT
Pain Therapeutics and Durect announced on Monday morning that Pfizer will discontinue development of Remoxy (Extended-Release oxycodone) and will return all rights to Pain Therapeutics.
In this article: PFE, DRRX, PTIE
Read
Tekmira And J&J’s Ebola Drugs Advance Towards Deployment In West Africa
Wednesday, October 22, 2014 9:07 AM EDT
Tekmira Pharmaceuticals (TKMR) and European drug developer Bavarian Nordic (BAVA.CO) are receiving significant attention in early trading on Wednesday morning with announcements that their two distinct approaches to Ebola, a therapeutic and vaccine respectively, are advancing.
In this article: BAVA.CO, JNJ, TKMR, CMRX
Read
With Latest Data, Investors Again Compare Synergy To The Billion-Dollar Ironwood Pharma
Tuesday, October 21, 2014 12:53 PM EDT
Synergy Pharmaceuticals (SGYP) is getting some much-needed love with phase 2 data, presented at a medical meeting on Monday, for the company's lead drug candidate, plecanatide in Irritable Bowel Syndrome (IBS-C).
In this article: SGYP, IRWD, ACT
Read
Illumina Puts Up Yet Another Glowing Quarter
Tuesday, October 21, 2014 8:19 AM EDT
Illumina (ILMN) yet again posted great quarterly numbers, surpassing consensus on revenue and earnings.
In this article: ILMN
Read
FDA Continues To Quash Interest In Repros Therapeutics
Friday, October 17, 2014 6:10 PM EDT
FDA put the brakes on Repros Therapeutics (RPRX) on Friday when it indicated that an upcoming meeting would not be the pre-NDA meeting investors expected. The stock dropped 40% in early trading.
In this article: RPRX
Read
1 to 11 of 11 Posts